Electroacupuncture for Postoperative Gastroparesis in Patients With Digestive Tract Tumors
Summary
The National Institutes of Health registered clinical trial NCT07546175, a prospective, multicenter, randomized, parallel-controlled, sham-controlled trial evaluating electroacupuncture for postsurgical gastroparesis syndrome in patients with digestive tract tumors. The trial will assess clinical efficacy via the Daily Diary of Gastroparesis Cardinal Symptom Index score at Day 14 and systematically evaluate safety, with a planned completion date of April 2026.
“This study aims to design and conduct a prospective, multicenter, randomized, parallel-controlled, sham-controlled clinical trial to evaluate the clinical efficacy of electroacupuncture for postsurgical gastroparesis syndrome (PGS) after digestive tract tumor surgery and systematically assess its clinical safety.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
NIH registered a new clinical trial (NCT07546175) studying electroacupuncture versus sham electroacupuncture for postsurgical gastroparesis syndrome following digestive tract tumor surgery. The trial will measure the Daily Diary of Gastroparesis Cardinal Symptom Index score at Day 14 as the primary endpoint and conduct systematic safety assessments, with enrollment across multiple centers. Healthcare providers treating post-surgical gastroparesis patients may wish to track trial progress, with a planned completion date of April 2026; the registration itself does not create immediate compliance obligations.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Clinical Study of Electroacupuncture for Postoperative Gastroparesis in Patients With Digestive Tract Tumors
N/A NCT07546175 Kind: NA Apr 22, 2026
Abstract
This study aims to design and conduct a prospective, multicenter, randomized, parallel-controlled, sham-controlled clinical trial to evaluate the clinical efficacy of electroacupuncture for postsurgical gastroparesis syndrome (PGS) after digestive tract tumor surgery and systematically assess its clinical safety. By measuring gastrointestinal hormones, inflammatory factors, proteomics and metabolomics, we intend to explore the mechanism underlying the improvement of postoperative gastrointestinal motility by electroacupuncture. We will identify the optimal population for electroacupuncture in PGS by analyzing baseline characteristics and efficacy correlations, to provide evidence for individualized clinical intervention. The primary endpoint is the Daily Diary of Gastroparesis Cardinal Symptom Index (GCSI-DD) score at Day 14 of treatment. Finally, based on clinical data, this study will define the eligible population and optimal protocol of electroacupuncture for PGS, and further standardize and promote its clinical application in postoperative complications of cancer.
Conditions: PGS
Interventions: Electroacupuncture, Sham electroacupuncture
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.